Intercambiar Trust Wallet Token TWT a Transfidelity FIDEL

Trust Wallet Token (TWT) 511 is a utility token that can only be used within the app. This will be used to incentivize all Trust Wallet users. What are the Incentives of (TWT)? Governance token that will be used by anyone who wants to take part in making decisions for adding new blockchain support, tokens and product features. Will also be collected as fees for submissions to the Trust Wallet repository 59. Discounts on DEX services and purchasing crypto within the app. Collectible Marketplace, anyone interested in trading, selling or buying digital collectibles can utilize the token in a user-friendly environment. DApp reviews and promotions to incentivize developers to work on DApps that contribute to further adoption of Web 3.0 on mobile devices. Affiliate and bounty rewards, the token can be converted to BNB or ETH, that can be used for Network Fees. Vouching and User reputation, users will be able to vouch for developers of products they enjoy to show the quality of the product to the rest of the Trust Ecosystem.

Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.